Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

50.20 +2.20 (+4.58%)
Streaming Delayed Price Updated: 10:40 AM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 380,737
Open 51.08
Bid (Size) 50.25 (2)
Ask (Size) 50.33 (6)
Prev. Close 48.00
Today's Range 50.11 - 51.78
52wk Range 29.16 - 49.66
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property

Performance

YTD
+37.8%
+37.8%
1 Month
+9.6%
+9.6%
3 Month
+53.7%
+53.7%
6 Month
+58.1%
+58.1%
1 Year
+54.5%
+54.5%

More News

Read More
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Represents an Affordable Growth Opportunity
Via Chartmill
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
Via Benzinga
Topics ETFs
Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)
Via StockStory
Topics Artificial Intelligence Intellectual Property
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
From Biogen Inc.
Via GlobeNewswire
3 Overrated Stocks with Questionable Fundamentals
Via StockStory
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Emerges as a Top Affordable Growth Stock
Via Chartmill
Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Cash-Producing Stock to Research Further and 2 We Brush Off
Via StockStory
Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Healthcare Stocks on Our Watchlist and 1 We Avoid
Via StockStory
Topics Stocks
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2
Via StockStory
Topics Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Unpopular Stock That Deserves a Second Chance and 2 Facing Headwinds
Via StockStory
2 Safe-and-Steady Stocks to Target This Week and 1 We Brush Off
Via StockStory
Integer Holdings, Astrana Health, Surgery Partners, IQVIA, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off
Via StockStory
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Fits the Affordable Growth Strategy with Strong Fundamentals and Attractive Valuation
Via Chartmill
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade
Via StockStory

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 50.20
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 10/09/25 10:40 AM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.67B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.